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Abstract
Aims: The SEISMIC study was an open-label, prospective, randomised study to assess the safety and feasibility
of percutaneous myoblast implantation in heart failure patients with implanted cardioverter-defibrillators (ICD).
Methods and results: Patients were randomised 2:1 to autologous skeletal myoblast therapy vs. optimal
medical treatment. The primary safety end-point was defined as the incidence of procedural and device
related serious adverse events, whereas the efficacy endpoints were defined as the change in global LVEF
by MUGA scan, change in NYHA classification of heart failure and in the distance achieved during a six-
minute walk test (6MW) at 6-month follow-up. Forty subjects were randomised to the treatment arm
(n=26), or to the control arm (n=14). There were 12 sustained arrhythmic events and one death after
episodes of ventricular tachycardia (VT) in the treatment group and 14 events in the control group (P=ns).
At 6-month follow-up, 6MW distance improved by 60.3±54.1 meters in the treated group as compared to
no improvement in the control group (0.4±185.7 meters; P=ns). In the control group, 28.6% experienced
worsening of heart failure status (4/14), while 14.3% experienced an improvement in NYHA classification
(2/14). In the myoblast-treatment arm, one patient experienced a deterioration in NYHA classification
(8.0%), whereas five patients improved one or two classes (20.0%; P=0.06). However, therapy did not
improve global LVEF measured by MUGA at 6-month follow-up.
Conclusions: These data indicate that implantation of myoblasts in patients with HF is feasible, appears to
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Introduction
Heart failure (HF) constitutes a growing patient population, in large
part due to advances in percutaneous revascularisation procedures,
optimised pharmacotherapeutic guidelines and HF care, which
contribute to an ageing population. An estimated five million patients
in the US suffer from clinically manifested HF and account for the
approximately one million hospital admissions per year.1 This
profound socio-economic burden merits the exploration of novel
therapeutic strategies for end-stage HF patients. Cell therapy may
provide a new option in the treatment of chronic left ventricular
dysfunction.
Skeletal myoblasts (SkMs) are an easily accessible source of
autologous precursor cells committed to a myogenic, functionally
contractile phenotype. Moreover, SkMs can be expanded extensively
in vitro to therapeutic relevant dosages from limited muscle biopsies.
SkMs are resistant to ischaemia, inflammatory conditions and
oxidative stress, and are able to form new myotubes in scarred
myocardium, which has been shown to contribute to the function of
damaged myocardium in large animal infarction models.2
In 2003, Menasche et al extended these observations to the
treatment of CAD patients with congestive HF undergoing surgical
revascularisation.3 We previously demonstrated the feasibility of
percutaneous autologous SkM transplantation following
endoventricular NOGA mapping and targeted intramyocardial
injection into the scar areas of chronically infarcted myocardium.4
We have now taken these studies further with the SEISMIC study,
which was designed as a multicentre, prospective, controlled,
randomised study to assess the safety and feasibility of
percutaneous intramyocardial transplantation of autologous SkMs
and to explore the efficacy in the treatment of congestive heart
failure patients. Study patients were stringently monitored for
arrhythmias possibly associated with cell therapy, and further
analysed using exercise testing, NYHA classification of HF,
Minnesota Living With Heart Failure Questionnaire (MLWHFQ) and
MUGA scan analysis of global LVEF at six months.
Methods
Study design
SEISMIC is a phase IIa, prospective, open-label, randomised study
performed at 13 sites in six European countries to assess the safety,
feasibility and cardiovascular effects of endoventricular autologous
SkM implantation by a catheter delivery system (MyoCell® and
MyoCath™; Bioheart Inc., Sunrise, FL, USA) in congestive HF
patients. Patients were randomised 2:1 to SkM cell therapy versus
optimal HF pharmacotherapy. All patients received prophylactic
treatment with amiodarone, four weeks prior to cell transplantation
for up to four weeks after SkM transplantation to minimise the risk of
ventricular arrhythmias (200 mg qd). Subjects assigned to the cell
treatment group received a skeletal muscle biopsy for SkM isolation
and culture. Myoblasts were intramyocardially injected into akinetic
segments under fluoroscopic guidance. Clinical evaluations were
scheduled at baseline, 1, 3, and 6 months.
The primary safety endpoint was defined as the proportion of
patients experiencing serious adverse events (SAEs) at three and six
months follow-up. Serious adverse events were defined as: a. any
adverse event that was fatal or life-threatening, b. led to prolonged
or required hospitalisation, c. resulted in any major medical
intervention or d. any sustained arrhythmia (>30 seconds). SAEs
were adjudicated by an independent DSMB committee. The
secondary safety endpoints included deviations of routine clinical
laboratory tests, 12-lead ECG recording, and the occurrence of
ventricular arrhythmias on 24 hour Holter monitoring. An additional
secondary safety objective was to investigate the safety of the
MyoCath™ catheter to percutaneously deliver the cellular graft.
The primary efficacy endpoint comprised the effect on global left
ventricular ejection fraction (LVEF) at three and six months as
assessed by a MUGA scan. Secondary efficacy endpoints included
the change in six-minute walk (6MW) distance. The overall
condition of the patients was assessed by NYHA classification of
HF, and the Minnesota Living With Heart Failure Questionnaire
(MLWHFQ), frequency and duration of hospitalisations, need for
medical treatment, and patient survival. Clinical parameters and
analyses of functional outcome were collected and analysed by an
independent clinical research organisation and independent core
laboratories respectively, all blinded to the treatment of the
individual patients.
Patient eligibility: in/exclusion criteria
The study intended to enrol 46 patients, randomised 2:1 to the
treatment arm and the control arm. Patients were eligible for study
enrolment if they had a diagnosis of ischaemic cardiomyopathy with
clinically manifest HF, NYHA classification II-III, and a global left
ventricular ejection fraction between 20 and 45%, as measured by
MUGA. Qualified patients had a defined akinetic region confirmed
by either left ventricular angiography or echocardiography. Optimal
pharmacological therapy was initiated at least two months prior to
screening, whereas an ICD was required to be fitted at least six
months prior to randomisation.
Exclusion criteria included CABG or PCI within three months prior to
cell implantation, HF secondary to valvular disease, ventricular
thrombus or significant aortic stenosis.
Quadriceps muscle biopsy and cell culture
expansion and transplantation
Autologous SkMs were isolated and cultured from approximately
10 grams of a skeletal muscle biopsy derived from the quadriceps
or gastronemicus muscle as previously described.4 The SkM grafts
were required to contain at least 50% SkMs, as determined by flow
cytometric analysis of CD56 and desmin immunostaining. The
myoblast cellular graft was intramyocardially injected into the
targeted treatment region utilising the MyoCath™ catheter delivery
system under fluoroscopic guidance as previously described.5
The treatment group received a dose in the range of 150-800
million cells, dependent on the size of ventricular scar tissue to be
treated. Since the cell concentration was maintained at
50 million cells/mL, the final number of injections varied per
patient. The volume per injection was 0.5 mL, whereas a maximum
number of 32 injections was allowed per implantation procedure.
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Holter monitoring of arrhythmia
To distinguish a possible pro-arrhythmic effect of intramyocardial
cell therapy, patients were assessed for pre-existing arrhythmias
using weekly 24-hour Holter monitoring, initiated at least six weeks
prior to MyoCell® implantation. Following intramyocardial SkM
transplantation, the patient was monitored by continuous telemetry
monitoring for a minimum of 72 hours after the procedure, followed
by 48 hour Holter monitoring. From the one-week follow-up period
onward, patients were subjected to 48 hour Holter monitoring every
week, for up to the four weeks post-transplantation, and at three
and six months. Any abnormal finding(s) or firing identified by the
ICD were assessed immediately by the investigative team at the
clinical site.
Statistical analysis
As SEISMIC was designed to be an exploratory randomised phase
IIa study to primarily assess the safety and feasibility of the
percutaneous MyoCell® transplantation procedure, and secondarily
to provide preliminary data regarding the efficacy of intramyocardial
SkM transplantation, no formal power calculations were performed.
Two-tailed t-tests were performed for all analyses and confidence
intervals are presented with 95% degree of confidence. A two-way
ANOVA with repeated measures was used for the comparison of
NYHA classification of HF and MUGA left ventricular ejection
fraction. All statistical tests used a significance level of α≤0.05.
The parametric assumption of homogeneity of variance for the two
treatment groups was checked using the F-test and normality of the
two samples was explored using the Wilk-Shapiro test for normality.
To support a non-parametric analysis, a 95% confidence for the
difference in medians is presented. For analysis of SAEs, a Chi-
square test (with continuity correction) was used, presented with a
95% confidence interval for the difference in proportions. If
expected cell frequencies were small (≤5), then Fisher’s exact test
was used instead.
Results
Patient cohort and baseline evaluation
Between October 2005 and May 2007, a total of 62 patients were
screened for enrolment in the study at 13 European sites. Of the
62 subjects, 12 failed screening, and were excluded. Three
subjects voluntarily withdrew during the screening process. The
remaining 47 patients were enrolled and randomised in a 2:1
fashion. Thirty-one patients were randomised to receive SkM
transplantation and 16 were randomised to the control group. Of the
31 patients randomised to the MyoCell® therapy group, five patients
voluntarily withdrew from the study following changes in the
German regulations concerning biopsies. Two patients withdrew
from the control group upon knowledge of their randomisation
allocation. Thus, a total of 40 patients entered the study, 26 of
whom entered the SkM cell therapy arm, and 14 entering the
control arm (Figure 1). Baseline clinical characteristics and
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Figure 1. Flow chart of the SEISMIC trial. From the 62 patients that
were initially screened, 47 were randomised due to screen failure of
15 patients. Five German patients that were allocated in the treatment
arm were withdrawn due to changed biopsy legislation. In the control
arm, two patients withdrew upon knowledge of their randomisation
allocation. 26 patients entered the treatment arm of the study and 14
patients entered the control arm.
Muscle biopsy and cell culturing
All procedures were well tolerated and uneventful, resulting in a
biopsy of 8.6±4.2 g. Two patients developed a post-procedural
haematoma that resolved without sequelae. On average,
920±302x106 myoblasts were generated with a viability of
96.7±2.1%. In all cultured cellular grafts, the CD56+ cell content
was at least 50% at the time point of cell harvest (89.0±13.2%
desmin+; 57.2%±23.9% CD56+).
Transplantation procedure
The transplantation procedure was successful in 26/27 patients
(96.3%). Patients scheduled for myoblast transplantation received
an average dose of 596±194x106 cells in 26±7 injections (range
12-35; in 18.8±6.8 cc [range 9-30 cc]).
In one patient, the implantation procedure was complicated by a
dissection of the left main coronary artery, the ascending and
descending aorta, upon dislocation of the MyoCath™ injection
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catheter during intramyocardial injection. The transplant procedure
was ceased after seven injections, with the coronary dissection
successfully treated by direct stent implantation, resulting in
recovery of coronary flow and stabilisation of the patient. The aortic
dissection was treated conservatively, and the patient recovered
without persistent myocardial or neurological sequelae
(CK
max
<300). This patient was excluded from the study resulting in
26 patients in total in the treatment arm.
All MACCE
An overview of the adjudicated SAEs is summarised in Table 2. No
unanticipated adverse events attributable to the SkM therapy were
reported, whereas no difference in the incidence of SAEs was
observed in the cell therapy and control arm. A total of 21 SAEs
occurred in 11 out of 26 patients subjected to SkM transplantation
(42%), as opposed to 23 SAEs occurring in five out of the 14 control
patients (36%; P=0.68). Specifically, 20 cardiovascular SAEs
occurred in 11 patients treated with SkM (11/26; 42%), whereas
18 cardiovascular events occurred in four patients in the control
arm (4/14;29%; P=0.39).
One patient in the myoblast therapy group died during the study
period (3.8%), whereas no deaths occurred in the control patient
group during study follow-up. This particular patient had a previous
medical history of ischaemic cardiomyopathy, impaired renal and
hepatic function, ventricular arrhythmias and ICD implantation four
years prior to enrolment. The MyoCell® implantation of 625 million
cells was uneventful. From day five to day 10, post-implantation, the
patient experienced several episodes of monomorphic, sustained
VT, which were successfully terminated via anti-tachycardia pacing.
In addition to beta-blockers and amiodarone, flecainide was
initiated, rendering the patient bradycardic and ICD/pacemaker
dependent. At 27 days, the patient deteriorated with the clinical
manifestation of progressive HF, which progressed into multi-organ
failure and death at 30 days post cell transplantation. The local
investigator and two independent cardiologists considered the
cause of death to be progression of terminal HF, with secondary
multiple organ failure, possibly provoked by flecainide with acute
Table 1. Baseline patient demographics and clinical characteristics.
Patient parameter measured MyoCell® Control p-value1
(n=26) (n=14)
Sex
Male 92% (24/26) 71% (10/14) 0.16
Female 8% (2/26) 29% (4/14)
Age (years)
mean±SD 59.2±8.64 61.9±8.38 0.35
(min - max) (32 - 72) (44 - 75)
Pharmacotherapy
Beta blockade 89% (23/26) 79% (11/14) 0.64
ACE inhibition or ARB 96% (25/26) 100% (14/14) 1.0
Diuretics 69% (18/26) 71% (10/14) 1.0
Anti-arrhythmic drugs 100% (26/26) 100% (14/14) 1.0
Coumarin derivative 35% (9/26) 36% (5/14) 1.0
Previous cardiovascular history
Myocardial infarction 100% (26/26) 100% (14/14) 1.0
Ventricular arrhythmia 73% (19/26) 71% (10/14) 1.0
Aborted sudden cardiac death 4% (1/26) 0% (0/14) 1.0
OOHA
ICD implanted prior 96% (25/26) 100% (14/14) 1.0
to study requirement
Previous PTCA 27% (7/26) 14% (2/14) 0.45
Previous CABG 23% (6/26) 21% (3/14) 0.44
Diabetes mellitus 31% (8/26) 14% (2/14) 0.45
CVA/TIA 0% (0/26) 14% (2/14) 0.14
LVEF (MUGA) 35±9% 33±11% 0.54
NYHA 0.32
NYHA I 0% (0/26) 0% (0/14)
NYHA II 62% (16/26) 79% (11/14)
NYHA III 38% (10/26) 21% (3/14)
NYHA IV 0% (0/26) 0% (0/14)
MLWHFQ (QOL) 40.4±21.9 45.1±29.1 0.32
Numbers are% (counts/available field sample size) or mean±1 Standard
Deviation. 1P-value is from a Fisher's exact test; SD standard deviation; ICD:
implantable cardioverter defribillator; MI: myocardial infarction; CABG:
coronary artery bypass graft; PTCA: percutaneous transluminal coronary
angioplasty; MLWHFQ: Minnesota Living With Heart Failure Questionnaire
Table 2. Serious adverse events & adverse events at 6-months.




Bradycardia 3.8% (1/26) 1 14.3% (2/14) 2 0.27
Ventricular fibrillation 3.8% (1/26) 1 0.0% (0/14) 0 1.0
Ventricular tachycardia 23.1% (6/26) 11 21.4% (3/14) 12 1.0
Idioventricular rhythm 0.0% (0/26) 0 14.3% (2/14) 2 0.12
Non-sustained VT with 
hospitalisation 3.8% (1/26) 1 0.0% (0/14) 0 1.0
Worsening of CHF 3.8% (1/26) 1 7.1% (1/14) 1 1.0
Hypotension 0.0% (0/26) 0 7.1% (1/14) 1 0.35
Pulmonary oedema 3.8% (1/26) 1 0.0% (0/14) 0 1.0
Aorta dissection 3.8% (1/26) 1 0.0% (0/14) 0 1.0
Pericarditis 3.8% (1/26) 1 0.0% (0/14) 0 1.0
Gastrointestinal
Diverticulitis 0.0% (0/26) 0 7.1% (1/14) 1 0.35
Gastroenteritis 3.8% (1/26) 1 0.0% (0/14) 0
Renal dysfunction 0.0% (0/26) 0 14.3% (2/14) 2 0.12
Pulmonary
Exacerbation COPD 3.8% (1/26) 1 0.0% (0/14) 0 1.0
Infection
Urinary tract 0.0% (0/26) 0 7.1% (1/14) 1 0.35
MRSA 0.0% (0/26) 0 7.1% (1/14) 1 0.35
Death 3.8% (1/26) 1 0.0% (0/14) 0 1.0
Total number of SAEs 21 23
Number of subjects 42.0% (11/26) 36.0% (5/14) 0.95
Subjects with
cell therapy-related SAEs2 30.8% (8/26)
Unanticipated cell 0.0% (0/26)
therapy-related SAEs3
Subjects reporting a particular event more than once are only counted once
using the most severe intensity for that event. '*' denotes statistical
significance at the 0.05 level. 1 P-value is from a Fisher's exact test. 2Cell-
therapy-related events are those events where relationship is possible/
probable/definite to MyoCell®, related to MyoCath™ device or related to
implant procedure. 3Unanticipated events have been identified through
a medical review of all serious adverse event information by a medically
qualified individual.
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renal failure. Alternatively, multiple episodes of VT not manageable
with anti-arrhythmic therapy may have initiated the progressive
deterioration of cardiac and renal function. Upon autopsy, no
evidence of thrombus formation or other signs of inflammation
could be detected at the site of intracardiac cell injection by
macroscopic or microscopic analysis. In the examined samples, the
pathologist did not find clusters of injected SkMs or newly formed
myotubes. A relation of this SAE with the MyoCell® implantation,
however, cannot be excluded.
Ventricular arrhythmias
All patients in the myoblast and control arm received oral
amiodarone therapy at the time of cell transplantation. In the control
patient group, three patients experienced one or more episodes of
sustained VT (3/14 pts; 21%), as opposed to seven patients in the
myoblast treatment group (6/26; 23%). Further, the 14 control
patients experienced a total 12 periods of sustained VT, as opposed
to 11 events in the 26 cell therapy patients. One of these patients in
the treatment group experienced two episodes of sustained VT that
required ablation of the ventricular focus localised at the myocardial
scar area where SkM were injected.
Previously, ventricular tachyarrhythmias were mainly reported in the
first four weeks following myoblast transfer. However, in the control
and the SkM group at hand, the number of patients and the
frequency of arrhythmic events were equally distributed among the
six month observation period and did not appear to correlate with the
dose of SkMs administered (data not shown). Thus, there was neither
a time, nor a dose relationship between tachyarrhythmic events and
the index procedure, as compared to the untreated control group.
Progression of congestive heart failure
Other cardiovascular SAEs included the worsening of congestive HF
of subjects requiring hospitalisation during the six month
observation period. This occurred on three occasions in the
26 patients of the SkM therapy group (3/26 patients; 11.5%) as
compared to one admission in the matched control group (7.1%).
A Kaplan-Meier survival curve for the time to onset of the first SAE
or death is shown in Figure 2.
Global ventricular ejection fraction by MUGA-scan
The average baseline LVEF in the myoblast treatment arm was
32.3±9.1% (n=24) as compared to 32.6±11.1% in the control arm
(n=14; Figure 3). One patient in the cell therapy group died prior to
the three month MUGA evaluation and was omitted from the analysis.
Sequential data were obtained in 24 of the 26 patients in the cell
therapy arm and in all 14 patients in the control arm. At six months
follow-up, global LVEF was 32.5±8.0% in the control patient group,
and 31.5±11.1% in the SkM-treated group (Figure 3; P=0.46).
NYHA heart failure classification and the
Minnesota Living With Heart Failure Questionnaire
During the 6-month study follow-up, the NYHA HF classification
deteriorated in 28.6% in the control arm (4/14), whereas 57.1%
remained stable. In the active cell therapy arm, only 8% showed a
deterioration of NYHA classification, whereas the majority of
patients even improved in 20.0% or remained unchanged (72.0%)
as compared to baseline (Figure 4A; P=0.06). Thus, a trend
towards improvement of NYHA classification of heart failure was
noted in the SkM-treated patients.
The number of patients that experienced improvement of MLWHFQ
over the six months follow-up increased from 33.3% to 52.2% with
cell therapy, whereas the patients who did not notice a change in
their quality of life was reduced from 41.7% to 8.7%. However, the
mean MLWHFQ score was not significantly different between both
arms (Figure 4B; P=0.99).
6-minute walking test
At baseline, the average distance walked in the six-minute walking
(6MW) test for patients randomised to the cell therapy arm was
lower than in the control arm (404.6±94.8 meters [n=23] vs.
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Figure 2. Kaplan-Meier survival curve for time to onset of first SAE or


















































Figure 3. Individual six month change in ejection fraction from
baseline to six month follow-up in the control group (A) and the
skeletal myoblast treated group (B) as measured by MUGA scan. The
mean data and standard deviation are denoted separately. No
significant change in LVEF was found between the myoblast treated
group and control.
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The distance walked in the control group remained virtually
unchanged at six month follow-up (+0.4±185 meters). In contrast,
the distance walked in the treated group improved by +60.3 meters
to 465.6±89.5 meters (Figure 4C: P=0.49). The walking distance
improved or remained unchanged in 87% of the myoblast-treated
patients, as opposed to 30.8% in the control arm. In contrast,
exercise tolerance deteriorated in 69.2% in the control arm as
opposed to 13.0% in the cell therapy arm.
Discussion
The rationale for the investigation of cell therapy for HF is based on
the assumption that development of HF is linked to irreversible loss
of contractile myocardium to below a certain threshold and that
myocardial function can be improved by replacing lost muscle with
cells that graft to, and function as native myocardium. In
experimental models, SkMs have been transplanted into infarcted
cardiac muscle and non-ischaemic, globally dilated myocardium,
and have been shown to subsequently develop into elongated,
striated muscle cells which retain characteristics of both skeletal
muscle and cardiac cells.6-9 In these models, intramyocardial
myoblast engraftment has been associated with a dose-dependent
improvement in LV function. Additionally, SkMs are able to release
trophic growth factors that exert an anti-fibrotic effect and enhance
cardiac performance and myocardial perfusion through the
stimulation of local angiogenesis.2,10
The safety concerns regarding endomyocardial SkM therapy
predominantly relate to a possible pro-arrhythmogenic effect of the
intramyocardial injection technique and the SkM graft. Irrespective
of whether cells were transferred as an adjunct to revascularisation
surgery, or by percutaneous endomyocardial injection, SkM therapy
was previously associated in a small number of patients with
recurrent premature ventricular systoles and (non)sustained
ventricular arrhythmias. This was seen particularly during the first
30 days after transplantation.3
In the SEISMIC trial, no significant difference was detected between
treatment groups, frequency of ventricular arrhythmic events or the
percentage of patients with documented ventricular tachyarrhythmia
via ICD interrogation (Table 2). SkM transplantation was neither
associated with an increased incidence of ventricular
tachyarrhythmias, nor in the absolute number of episodes in the
treatment group. In the control patient group, 21% of the patients
experienced one or more episodes of serious ventricular
tachyarrhythmias (a total of 12 episodes of VT/VF), as opposed to
27% in the myoblast treatment group (total of 12 episodes of VT/VF).
Ablation of a ventricular focus was indicated in one patient due to
refractory tachyarrhythmias at 10 and 16 weeks following SkM
transplantation. Although a causal relationship between these
tachyarrhythmic events and the SkM transplantation can not be
excluded, the time interval between the cell injection procedure and
the onset of VTs renders a relationship less probable. The SkMs
were injected in scar tissue that by itself could give rise to
ventricular tachyarrhythmias. In another patient, tachyarrhythmias
at five days following SkM therapy may have provoked deterioration
and progression into terminal HF. Even though this particular
patient was known with multiple episodes of VT before cell injection
and an ICD was implanted four years earlier, causality between the
intramyocardial injections and the VTs cannot be ruled out.

























































































































































Figure 4. Six month change from baseline in NYHA Class (A), Minnesota Living With Heart Failure Questionnaire (B) and exercise tolerance (C).
NYHA Class deteriorated in 28.6% of the cases in the control arm, whereas 57.1% remained unchanged. In the active cell therapy arm NYHA
classification either improved or remained unchanged (20.0% and 72.0% respectively, P=0.06). Also in the Minnesota Living With Heart Failure
Questionnaire a trend to improvement was seen in treated patients (light red) vs. control patients (dark red), but this difference was not statistically
significant (p=0.99). Exercise tolerance was measured by six minute walking test in treated (dark red) and control (light red) patients. Although a
trend to an increased exercise tolerance was seen, the difference between the treated and control group was not significant (p=0.49).
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correlation between tachyarrhythmic events and the index
procedure, a pro-arrhythmic effect associated with the myoblast
transplantation procedure in these two patients cannot be
excluded. However, the current data provide a basis to further
explore the therapeutic value of SkM transplantation in larger
randomised and placebo-controlled trials with prophylactic
amiodarone and ICD implantation.
In various pre-clinical animal models, SkM therapy has been shown
to reduce myocardial remodelling, impede ECM deposition and
cardiomyocyte apoptosis and replenish lost cardiomyocytes in the
chronic scar by introducing new contractile myocytes into the
region of dysfunction.2,6,11 Immunohistological and patch clamp
studies of myoblasts have shown effective re-population of the
fibrotic tissue and transition from a “fast” to a “slow twitch”
phenotype upon cardiac transplantation eventually leading to
restoration of contractile function. Skeletal myoblast therapy is to
date the only regenerative cell therapy approach primarily aimed at
neomyogenesis, rather than neoangiogenesis in the myocardial
scar, in post AMI heart failure patients.
In the MAGIC trial, intramyocardial SkM transplantation as an
adjunctive to CABG was studied in patients with ischaemic HF with
an ejection fraction under 35%.12 Although SkM transfer failed to
augment the restoration of regional and global LV function as
determined by echocardiography in these patients undergoing
surgical revascularisation, an improvement in LV dimensions was
observed in the high dose cell group. In contrast, in the open-label,
dose-escalating, randomised MYOHEART and CAUSMIC trials,
trends towards beneficial clinical and functional effects of myoblast
therapy were reported in patients with ischaemic heart failure
following endoventricular injection in respectively 20 and
12 patients.13
In the current study, SkM therapy appeared to attenuate further
deterioration of NYHA classification of HF, with an improvement in
exercise tolerance in a 6MWT, as opposed to a lack of improvement
in the control arm. However, this could not be substantiated by an
improvement in global LVEF, quantified by nuclear ventriculography.
The lack of a clear effect on global LVEF can be partly explained by
our previous studies in preclinical and clinical myoblast
transplantation, which suggested that on short term, akinesia in
scarred or hibernating myocardium might be compensated by
hyper-contractility in remote myocardial segments to preserve
global LV function. A possible beneficial effect of stem cell therapy
leading to improved local wall motion in the afflicted wall segment
may be concealed by normalisation of the compensatory hyper-
contractility in remote wall segments, resulting in a modest overall
effect on global cardiac function. Moreover, the long term follow-up
of patients with LV dysfunction by conventional echocardiographic
or scintigraphic LVEF quantification is based on the presumption of
a comparable haemodynamic state of patients at baseline and
follow-up and cannot be corrected for change in LV loading. As
myocardial cell therapy aims to improve the contractile function and
haemodynamic state, comparing LVEF with the assumption of static
LV loading may underestimate the beneficial effect on LV function.
Invasive haemodynamic analysis of systolic and diastolic LV
function by the analysis of pressure volume-loop relations under
dynamic LV loading (LV unloading by use of gradual preload
reduction), can however provide load-independent indices of global
and intrinsic systolic and diastolic function. Indeed, in a long term
follow-up of patients that received endoventricular myoblast
injection, pressure-volume relation analysis provided proof of
improved systolic and diastolic function at six and 12-month follow-
up, whereas nuclear radiography and magnetic resonance imaging
failed to reflect this improvement.14
Although SEISMIC suggests that the use of SkM therapy is safe, the
mixed results on functional efficacy endpoints, coupled with the
general underpowering of the study, render any interpretation
inconclusive. Further, since the current trial was an open-label
study, a potential effect of patient bias on the positive effects on
clinical endpoints cannot be ruled out, and underscores the
necessity to conduct appropriately powered clinical studies to
evaluate cell therapy, blinded to both clinical staff and patients, with
outsourcing of study end point analyses to independent core
laboratories. Hence, the recently initiated MARVEL study seeks to
explore the therapeutic efficacy of NOGA guided endomyocardial
myoblast therapy in chronic LV dysfunction in a prospective,
randomised, double-blinded, placebo-controlled study enrolling
390 patients in up to 35 US and EU clinical centres.
Conclusion
The current study sought to define the safety and feasibility of
percutaneous intramyocardial transplantation of autologous SkM in
40 patients with chronic HF with an ischaemic origin. One could
argue whether this would be the most appropriate target
population to provide proof of principle of a neomyogenesis therapy
concept, since end-stage heart failure patients may lack the
plasticity to respond to reverse remodelling by stem cell therapy.
The current study failed to detect a benefit on global LV function,
possibly because it was outweighed by the advanced LV
dysfunction in end-stage HF or fell beyond the detection limits of
radionuclide ventriculography. In addition, the small sample size in
a heterogeneous population could have further concealed a
possible beneficial effect on global LVEF. Since the studies in the
chronic HF stem cell therapy field are still at a very preliminary
stage, they are exploratory in nature, and thus by virtue,
underpowered. Therefore a true evaluation of efficacy and safety
cannot be guaranteed by the study at hand, and should be
validated in forthcoming phase II/III studies. However, the current
study does provide encouraging feasibility data regarding the
endomyocardial stem cell treatment, and suggests some clinical
benefit of SkM therapy in HF patients.
Funding sources
The study was supported by Bioheart Inc, Sunrise, Florida, USA.
References
1. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and
management of chronic heart failure in the adult. J Am Coll Cardiol.
2005;46:e1-82.
2. Menasche P. Skeletal myoblasts and cardiac repair. J Mol Cell
Cardiol. 2008;45:545-53.
139_2009028_00_Duckers_AOPjune_OK805  17/01/11  13:03  Page811
- 812 -
Skeletal myoblast transplantation in heart failure
3. Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, 
Pouzet B, Bel A, Sarateanu S, Scorsin M, Schwartz K, Bruneval P,
Benbunan M, Marolleau JP, Duboc D. Autologous skeletal myoblast
transplantation for severe postinfarction left ventricular dysfunction. J Am
Coll Cardiol. 2003;41:1078-83.
4. Smits PC, van Geuns RJ, Poldermans D, Bountioukos M,
Onderwater EE, Lee CH, Maat AP, Serruys PW. Catheter-based intramy-
ocardial injection of autologous skeletal myoblasts as a primary treatment
of ischemic heart failure: clinical experience with six-month follow-up.
J Am Coll Cardiol. 2003;42:2063-9.
5. Ince H, Petzsch M, Rehders TC, Chatterjee T, Nienaber CA.
Transcatheter transplantation of autologous skeletal myoblasts in postin-
farction patients with severe left ventricular dysfunction. J Endovasc Ther.
2004;11:695-704.
6. Dowell JD, Rubart M, Pasumarthi KB, Soonpaa MH, Field LJ.
Myocyte and myogenic stem cell transplantation in the heart.
Cardiovasc Res. 2003;58:336-50.
7. van den Bos EJ, Thompson RB, Wagner A, Mahrholdt H,
Morimoto Y, Thomson LE, Wang LH, Duncker DJ, Judd RM, Taylor DA.
Functional assessment of myoblast transplantation for cardiac repair with
magnetic resonance imaging. Eur J Heart Fail. 2005;7:435-43.
8. McConnell PI, del Rio CL, Jacoby DB, Pavlicova M, Kwiatkowski P,
Zawadzka A, Dinsmore JH, Astra L, Wisel S, Michler RE. Correlation of
autologous skeletal myoblast survival with changes in left ventricular
remodeling in dilated ischemic heart failure. J Thorac Cardiovasc Surg.
2005;130:1001.
9. Maurel A, Azarnoush K, Sabbah L, Vignier N, Le Lorc’h M, Mandet C,
Bissery A, Garcin I, Carrion C, Fiszman M, Bruneval P, Hagege A,
Carpentier A, Vilquin JT, Menasché P. Can cold or heat shock improve
skeletal myoblast engraftment in infarcted myocardium? Transplantation.
2005;80:660-5.
10. Formigli L, Perna AM, Meacci E, Cinci L, Margheri M, Nistri S,
Tani A, Silvertown J, Orlandini G, Porciani C, Zecchi-Orlandini S, Medin J,
Bani D. Paracrine effects of transplanted myoblasts and relaxin on post-
infarction heart remodelling. J Cell Mol Med. 2007;11:1087-100.
11. van den Bos EJ, Davis BH, Taylor DA. Transplantation of skeletal
myoblasts for cardiac repair. J Heart Lung Transplant. 2004;23:1217-27.
12. Menasche P, Alfieri O, Janssens S, McKenna W,
Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B,
Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagège AA. The
Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial.
Circulation. 2008;117:1189-200.
13. Dib N, Dinsmore J, Lababidi Z, White B, Moravec S, Campbell A,
Rosenbaum A, Seyedmadani K, Jaber WA, Rizenhour CS, Diethrich E.
One-year follow-up of feasibility and safety of the first U.S., randomized,
controlled study using 3-dimensional guided catheter-based delivery of
autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC
study). JACC Cardiovasc Interv. 2009;Jan;2:9-16.
14. Steendijk P, Smits PC, Valgimigli M, van der Giessen WJ,
Onderwater EE, Serruys PW. Intramyocardial injection of skeletal
myoblasts: long-term follow-up with pressure-volume loops. Nat Clin Pract
Cardiovasc Med. 2006;3 Suppl 1:S94-100.
139_2009028_00_Duckers_AOPjune_OK805  17/01/11  13:03  Page812
